Genix Pharmaceuticals Corporation announced that it has entered into an exclusive Canadian licensing and supply agreement with Acme Generics LLP for the manufacture, sale, marketing and distribution of Canada's first available generic version of Synthroid® (Levothyroxine sodium), a widely prescribed treatment for hypothyroidism. Hypothyroidism (low thyroid hormone), or thyroid dysfunction, affects around 10% of Canadians aged 45 years or older. Levothyroxine is a thyroid medicine that replaces a hormone (T4) normally produced by your thyroid gland to regulate the body's energy and metabolism and is used to treat hypothyroidism. GENIX will pay ACME a total licensing fee of USD 350,000 (the "Transaction") for the exclusive Canadian rights which includes eleven dosages of Levothyroxine sodium. ACME will assist GENIX and its regulatory consultants to file Abbreviated New Drug Submissions (ANDS) with Health Canada to obtain regulatory approvals for legal sale of the drugs in Canada. The Agreement is subject to TSX-V approval.